Influx Healthtech Limited, established on September 28, 2020, transitioned from a private to a public company in May 2022. It operates as a healthcare product-focused Contract Development and Manufacturing Organization (CDMO) based in Mumbai, India. The company is primarily engaged in the manufacturing of dietary and nutritional supplements, gym/sports supplements, veterinary feeds, Ayurvedic products, cosmetics, and homecare goods. Influx serves small to medium marketing and distribution brands by offering end-to-end support in product development and manufacturing, thereby facilitating further branding and distribution by its clients.
Influx Healthtech operates three manufacturing plants in Thane, Maharashtra, certified with GMP, HACCP, ISO 22000, and Halal standards. Its facilities are equipped with advanced machinery, quality control departments, and skilled personnel, ensuring high-quality outputs. The company’s diverse portfolio includes items such as soft gelatin capsules, tablets, liquid fillings, protein bars, creams, oils, soaps, and gummies. It caters to segments like nutraceuticals, cosmetics, Ayurvedic/herbal products, veterinary feed supplements, and homecare products.
The founders, Mr. Munir Abdul Ganee Chandniwala and Ms. Shirin Munir Ahmed Chandniwala, have positioned Influx Healthtech as a reliable third-party manufacturer specializing in Active Pharmaceutical Ingredients (APIs) and finished dosage forms like capsules and tablets. The company is planning an initial public offering (IPO) of 60,00,000 equity shares, comprising a fresh issue of 46,32,000 shares and an offer for sale of 13,68,000 shares, signaling intent for expansion and market penetration.
Influx Healthtech combines technical expertise with a commitment to quality, making it a promising business for traders interested in the nutraceutical and healthcare manufacturing space. Its competitive edge lies in diversifying across multiple high-growth sectors, utilizing advanced manufacturing capabilities, and supporting its clients’ product development needs.
